Daily statin reduced the risk of cardiovascular disease in people living with HIV, large NIH study found
On Apr. 11, 2023, a National Institutes of Health (NIH) clinical trial was stopped early because a daily…
Biotechnology | HIV | Life Science News | NIH | Vaccine
Experimental HIV vaccine regimen safe but ineffective, study found
On Jan. 18, 2023, the National Institutes of Health (NIH) announced that an investigational HIV vaccine regimen tested…
Moderna announced mRNA-1345, an investigational RSV Vaccine, met primary efficacy endpoints in phase 3 trial
On Jan. 17, 2023, Moderna announced positive topline data from its ConquerRSV Phase 3 pivotal efficacy trial of…
Relief reports that its U.S. collaboration partner announced DSMB recommended termination of ACTIV-3b study in critical COVID-19
On May 26, 2022, RELIEF THERAPEUTICS announced that the parent company, NRx Pharmaceuticals, of its collaboration partner with…
CureVac provided update on phase 2b/3 trial of first-generation COVID-19 vaccine candidate, CVnCoV
On Jun. 16, 2021, CureVac announced results of the second interim analysis of its international pivotal Phase 2b/3…
DSMB confirmed CureVac pivotal phase 2b/3 study for first-generation COVID-19 vaccine candidate
On May 28, 2021, CureVac announced that the independent Data Safety Monitoring Board (DSMB)confirmed that the pivotal Phase…
Investigational AstraZeneca vaccine prevented COVID-19
On Mar. 22, 2021, the NIH announced that results from a large clinical trial in the U.S. and…
Abivax stopped phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy
On Mar. 5, 2021, Abivax announced tthat it was halting the miR-AGE phase 2b/3 clinical trial in high-risk…
NIH-sponsored ACTIV-3 clinical trial closed enrollment into two sub-studies
On Mar. 4, 2021, the NIH announced that the ACTIV-3 clinical trial evaluating the safety and efficacy of…
RedHill’s phase 2/3 COVID-19 study of opaganib passed second DSMB with unanimous recommendation
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
Biotechnology | COVID-19 | FDA | Life Science News | Vaccine
Moderna received FDA Advisory Committee vote supporting EUA for vaccine against COVID-19 in the U.S.
On Dec. 17, 2020, Moderna confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological…
Moderna announced primary efficacy analysis in phase 3 COVE study for COVID-19 vaccine candidate
On Nov. 30, 2020, Moderna announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273…
Moderna amended supply agreement with UK Government for 2 million doses of mRNA COVID-19 vaccine
On Nov. 29, 2020, Moderna announced a supply agreement with the United Kingdom (UK) government for an additional…
Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
DSMB analysis recommended continuance of P3 COVID-19 ARDS trial
On Nov. 11, 2020, Mesoblast announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with…
Johnson & Johnson temporarily paused all dosing in Janssen COVID-19 vaccine candidate clinical trials
On Oct. 12, 2020, Johnson & Johnson announced temporarily paused further dosing in all our COVID-19 vaccine candidate…
Humanigen announced review of lenzilumab phase 3 study in COVID-19 by Data Safety Monitoring Board
On Sept. 14, 2020, Humanigen announced its Phase 3 registration trial of lenzilumab in patients with COVID-19 was…
The NIH halted clinical trial of hydroxychloroquine
On Jun. 20, 2020, the National Institutes of Health (NIH) announced that a clinical trial to evaluate the…